Kathleen Laporte - 10 Jun 2026 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Reporting relationship: Director
Issuer ticker: BOLT
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:14:03 UTC
Prior SEC filing: 30 Jan 2026
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William P. Quinn, Attorney-in-Fact

Key filing fact

Kathleen Laporte filed Form 4 for Bolt Biotherapeutics, Inc. (BOLT) on 11 Jun 2026.

Key facts

This page summarizes Kathleen Laporte's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:14.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001196201 Primary reporting owner

LAPORTE KATHLEEN

Relationship: Director
Address: C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ William P. Quinn, Attorney-in-Fact
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,000
Change %
Price: $0.000000^*
Shares after: 5,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $4.43
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.